Kinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Kinnate Biopharma

29/03/2024 19:05

* Kinnate Biopharma Inc  KNTE.OQ  reported a quarterly
adjusted
loss of 36 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -72 cents.  The mean expectation of six analysts
for the quarter was for a loss of 42 cents per share. Wall
Street expected results to range from -50 cents to -37 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kinnate Biopharma Inc's reported EPS for the quarter was a
loss
of 36 cents​.
    * The company reported a quarterly loss of $17.06 million.
    * Kinnate Biopharma Inc shares had risen by 12.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $2.50 

This summary was machine generated from LSEG data March 29 at
07:05 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.42          -0.36          Beat
 Sep. 30 2023      -0.67          -0.65          Beat
 Jun. 30 2023      -0.75          -0.68          Beat
 Mar. 31 2023      -0.73          -0.73          Met